Seghatchian M J, Ala F
Quality Assurance, North London Blood Transfusion Centre, UK.
Transfus Sci. 1995 Jun;16(2):99-105. doi: 10.1016/0955-3886(95)00000-n.
Since the initial reports, in the early 1960s, of Transfusion-Associated Graft-versus-Host Disease (TA-GVHD) in infants with congenital immunodeficiency and individuals with various haematological malignancies, our knowledge of this rare but uniformly fatal consequence of transfusion has improved. Today, it is possible to define with greater certainty patients who are most at risk; the blood components capable of causing TA-GVHD; and the methods for preventing TA-GVHD. In the absence of effective treatment for TA-GVHD, attention is currently focused on potential preventative measures, in particular using u.v.- or gamma-irradiated blood components. This overview deals with some general aspects of the current concepts and future trends in treatment of TA-GVHD.
自20世纪60年代初首次报道先天性免疫缺陷婴儿和各种血液系统恶性肿瘤患者发生输血相关移植物抗宿主病（TA-GVHD）以来，我们对这种罕见但无一例外致命的输血后果的认识有所提高。如今，能够更确切地界定哪些患者风险最高；哪些血液成分会导致TA-GVHD；以及预防TA-GVHD的方法。由于缺乏针对TA-GVHD的有效治疗方法，目前的注意力集中在潜在的预防措施上，特别是使用紫外线或γ射线照射的血液成分。本综述探讨了TA-GVHD治疗的当前概念和未来趋势的一些一般方面。
